Targeting the kappa opioid receptor with an agonist is a new pharmacy strategy for treating moderate to severe CKD-associated ...

Having an itch that you just can’t scratch is one of the most frustrating experiences – but it might actually be beneficial ...

A collaborative study led by De’Broski R. Herbert of the School of Veterinary Medicine at the University of Pennsylvania and ...

Now imagine an itch that refuses to go away, no matter how hard or long you scratch. That persistent itch, or pruritus, may ...

Significant progress is being made in the fight against Chronic Kidney Disease-associated Pruritus but sustaining strong ...

Shares of Tharimmune Inc. shot up more than 100% in early trading Oct. 30 as the firm disclosed regulatory backing to launch a phase II trial this quarter testing TH-104, a transdermal buccal film ...

Tharimmune, Inc. (NASDAQ:THAR) shares are moving higher Wednesday after the company announced it received overall positive ...

Big news out of New Jersey this morning as a %Biotech company said it received “positive feedback” from the European ...

TH104, the Company's lead candidate for moderate-to-severe pruritus in chronic liver disease, showed no opioid withdrawal effects, reinforcing ...

Tharimmune (THAR) received feedback from a Scientific Advice meeting with the European Medicines Agency that included guidance on a planned ...

Tharimmune, Inc. (NASDAQ:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces that ...